This article was published on August 16, 2020

Are you safe from COVID-19 if you’ve had the common cold?

Are you safe from COVID-19 if you’ve had the common cold? Image by: Pexels

An article in Science recently generated a lot of interest by providing a possible explanation of why COVID-19 can be deadly to some yet go virtually unnoticed in others.

Scientists at La Jolla Institute for Immunology in California showed that infection with common cold coronaviruses can generate an immune response that resembles key pieces of the immune response generated by SARS-CoV-2 – the virus that causes COVID-19. This raises the possibility that previous infection with one of the milder coronaviruses could make COVID-19 less severe. But how likely is this? And how does this relate to what we already know about coronaviruses?

A few weeks ago, a different article sat at the center of the SARS-CoV-2 immunity debate. This one showed that the antibody response to SARS-CoV-2 may decline over time.

[Read: Here’s how researchers found coronavirus in a cat — but don’t panic]

The <3 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!

The findings raised concern that SARS-CoV-2 could infect a person many times and that a vaccine might not generate lasting protection. But the article focused on just one arm of the immune response, the B cells, which produce antibodies that help to clear an infection.

T cells are also key to the immune response against viruses. They play a variety of roles, among them helping B cells to mature into disease-fighting machines. The article by Jose Mateus and colleagues at La Jolla Institute for Immunology is important because it shows that people keep T cells from the milder coronaviruses long enough to potentially interact with a new challenge by SARS-CoV-2 and that those T cells might even recognize SARS-CoV-2 and help to clear the infection.

Antibodies attacking a coronavirus.
Antibodies latching onto a coronavirus to neutralize it. Kateryna Kon/Shutterstock

The case for cross-immunity

For epidemiologists, the evidence of waning immunity and cross-immunity didn’t come as a surprise. A study from 1990 showed that soldiers infected with one of the milder coronaviruses didn’t retain immunity for much longer than a year. Also, the boom-bust cycle that the milder coronaviruses undergo from year to year can be explained by a mix of waning immunity and cross-immunity.

The milder coronaviruses can generate similar antibodies to the ones that are generated by the coronaviruses that cause Sars and Mers. These antibodies are so similar that they nearly tricked a British Columbia care facility into thinking they had an outbreak of Sars after the Sars epidemic had been declared over. In fact, the outbreak was caused by OC43, one of the coronaviruses that causes the common cold.

Nevertheless, infections that generate structurally similar antibodies don’t necessarily provide cross-protection in a medically meaningful way.

We’re still just not sure

Evidence for cross-protection between all but the most closely related coronaviruses is scant.

It is difficult to say whether the milder coronaviruses protect against SARS-CoV-2 partly because we have done so little surveillance on them. Ideally, we would be able to look at historical data to identify which communities experienced major outbreaks of each milder coronavirus strain over the past few years and then see if there is a link with less severe COVID-19 cases.

Challenge studies, in which a person is intentionally infected with a milder coronavirus strain and then exposed to SARS-CoV-2, could also address the question but are dangerous and ethically fraught. For now, all we can say is that the possibility that the common coronaviruses might protect against SARS-CoV-2 remains just that – a possibility. Indeed, Mateus and colleagues describe this theory as “highly speculative.”The Conversation

This article is republished from The Conversation by Stephen Kissler, Postdoctoral Researcher, Immunology and Infectious Diseases, University of Cambridge under a Creative Commons license. Read the original article.

Get the TNW newsletter

Get the most important tech news in your inbox each week.

Also tagged with